index,source,r,target
33436035,clinical utility of CSF AD biomarkers,in,β-amyloid (Aβ) positron emission tomography (PET) status
33436035,MCI,in,CSF biomarkers (cutoffs of 642.1 pg/mL for Aβ42 0.060 for Aβ42/Aβ40 0.315 for t-tau/Aβ42 and 0.051 for p-tau/Aβ42 respectively)
33436035,CSF (n = 143),in,Aβ-PET status
33436035,Aβ-PET status,in,CSF biomarkers (cutoffs of 642.1 pg/mL for Aβ42 0.060 for Aβ42/Aβ40 0.315 for t-tau/Aβ42 and 0.051 for p-tau/Aβ42 respectively)
33436035,CSF (n = 143),in,Aβ-PET status
33436035,CSF (n = 143),in,CSF biomarkers (cutoffs of 642.1 pg/mL for Aβ42 0.060 for Aβ42/Aβ40 0.315 for t-tau/Aβ42 and 0.051 for p-tau/Aβ42 respectively)
33436035,Prediction of AD,provided,(CSF)
33436035,Prediction of AD,provided,271 underwent baseline amyloid PET (n = 128 with overlapping CSF and Aβ-PET and 143 without CSFs)
33436035,(29 CN 58 SCD 29 MCI and 23 AD),provided,(CSF)
33436035,(29 CN 58 SCD 29 MCI and 23 AD),provided,271 underwent baseline amyloid PET (n = 128 with overlapping CSF and Aβ-PET and 143 without CSFs)
33436035,MCI,determined,Aβ-PET status
33436035,CSF (n = 143),applied,CSF biomarker cutoffs
33436035,MCI,applied,CSF biomarker cutoffs
33436035,CSF biomarker cutoffs,determined based on,Aβ-PET status
33436035,CSF biomarker cutoffs,determined based on,CSF biomarkers (cutoffs of 642.1 pg/mL for Aβ42 0.060 for Aβ42/Aβ40 0.315 for t-tau/Aβ42 and 0.051 for p-tau/Aβ42 respectively)
33436035,AD-like CSF signature,determined by,Aβ-PET-based cutoffs
35061102,both beta-amyloid (Aβ),in,large cohort of MCI subjects
35061102,both beta-amyloid (Aβ),in,AD pathogenesis
35061102,ApoE4,in,large cohort of MCI subjects
35061102,ApoE4,in,AD pathogenesis
35061102,CSF Aβ42 total tau (t-tau),in,large cohort of MCI subjects
35061102,MCI-progression groups,on,CSF biomarker levels
35061102,MCI-stable individuals,in,large cohort of MCI subjects
35061102,MCI-stable individuals,in,AD pathogenesis
35061102,both CSF amyloid-β burden and tau aggregation,in,AD pathogenesis
35061102,﻿ApoE4,for,Alzheimer's disease (AD)
35061102,ApoE4,with,CSF Aβ42 total tau (t-tau)
35061102,ApoE4,with,tau181 (p-tau)
35061102,diagnosis of MCI-stable MCI-AD converters,progressing to,other dementias
35061102,MCI,progressing to,other dementias
35061102,other dementias,from,German Dementia Competence Network
35061102,total sample ApoE4 carriers,had,lower concentrations of CSF Aβ42
35061102,lower concentrations of CSF Aβ42,increased concentrations of t-tau,p-tau
35061102,MCI-progression groups,showed,significant influence of ApoE4 carriership
35061102,significant influence of ApoE4 carriership,on,CSF biomarker levels
35061102,ApoE4,having decreased,CSF Aβ 42 levels
35061102,CSF Aβ 42 levels,increased concentration of t-tau,p-tau
31834392,tau biomarkers,in,mild cognitive impairment (MCI)
31834392,tau biomarkers,in,Alzheimer disease (AD)
31834392,Levels of β-amyloid 1-42 (Aβ1-42) tau,phosphorylated,tau 181
31834392,Levels of β-amyloid 1-42 (Aβ1-42) tau,phosphorylated,(pTau181) ratio of tau
31834392,Levels of β-amyloid 1-42 (Aβ1-42) tau,phosphorylated,pTau181
31834392,pTau181,to,Aβ1-42 ratio
31834392,CSF biomarkers,in,clinical diagnosis of prodromal AD
24132375,CSF β-amyloid 1-42 (Aβ1-42) total tau (t-tau),phosphorylated,tau (p-tau)
24132375,baseline CSF values,in,CSF values
30611311,Baseline CSF biomarkers,on,age gender APOE ε4 genotype
30611311,Baseline CSF biomarkers,in,144 MCI subjects
30611311,(Aβ) 1,on,age gender APOE ε4 genotype
30611311,(Aβ) 1,in,144 MCI subjects
30611311,Aβ42/40 Tau,on,age gender APOE ε4 genotype
30611311,Aβ42/40 Tau,in,144 MCI subjects
30611311,pTau181,on,age gender APOE ε4 genotype
30611311,pTau181,in,144 MCI subjects
30611311,MCI stage of AD,in,144 MCI subjects
30611311,MCI patients,on,age gender APOE ε4 genotype
30611311,MCI patients,in,144 MCI subjects
30611311,cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD),ordering,cerebrospinal fluid (CSF) biomarkers of Alzheimer
30611311,improbable AD (ES = 1),to,probable AD (ES = 4)
30611311,possible AD (ES = 2 or 3),to,probable AD (ES = 4)
30611311,mild cognitive impairment (MCI) stage of AD,to,dementia stage of disease
30611311,mild cognitive impairment (MCI) stage of AD,to,Alzheimer's disease dementia (ADD)
30611311,MCI stage of AD,on,age gender APOE ε4 genotype
30611311,age gender APOE ε4 genotype,score in,144 MCI subjects
35925685,CSF amyloid-β42 (Aβ42),on,CSF and PiB biomarkers
35925685,Aβ40 total tau (Tau),on,CSF and PiB biomarkers
35925685,relative orderings of Alzheimer disease biomarkers,on,CSF and PiB biomarkers
35925685,(pTau181),on,CSF and PiB biomarkers
35925685,11C-Pittsburgh Compound-B (PiB),on,CSF and PiB biomarkers
35925685,CSF Aβ42,on,CSF and PiB biomarkers
35925685,CSF Aβ42,in,APOE ɛ4 non-carriers
35925685,Aβ42/Aβ40 ratio (with increase),on,CSF and PiB biomarkers
35925685,Aβ42/Aβ40 ratio (with increase),in,APOE ɛ4 non-carriers
35925685,Tau,on,CSF and PiB biomarkers
35925685,Tau,in,APOE ɛ4 non-carriers
35925685,pTau181 (with decrease),on,CSF and PiB biomarkers
35925685,pTau181 (with decrease),in,APOE ɛ4 non-carriers
35925685,Aβ42 and Aβ42/Aβ40 ratio,on,CSF and PiB biomarkers
35925685,Aβ42 and Aβ42/Aβ40 ratio,in,APOE ɛ4 non-carriers
35925685,relative orderings of Alzheimer disease biomarkers,including,CSF amyloid-β42 (Aβ42)
35925685,relative orderings of Alzheimer disease biomarkers,including,Aβ40 total tau (Tau)
35925685,CSF amyloid-β42 (Aβ42),phosphorylated,(pTau181)
35925685,Aβ40 total tau (Tau),phosphorylated,(pTau181)
35925685,CSF Aβ42,for,Tau
35925685,CSF Aβ42,for,pTau181 (with decrease)
35925685,Aβ42/Aβ40 ratio (with increase),for,Tau
35925685,Aβ42/Aβ40 ratio (with increase),for,pTau181 (with decrease)
35925685,relative orderings of Alzheimer disease biomarkers,across,modification effect of APOE ɛ4
30419087,CSF NfL,were associated with,risk of MCI
30419087,Ng levels,were associated with,risk of MCI
30419087,risk of MCI,compared with,CSF T-tau
30419087,risk of MCI,compared with,P-tau
30419087,CSF T-tau,for,risk of MCI
30419087,P-tau,for,risk of MCI
30419087,risk of MCI,whether,CSF amyloid-β (Aβ42)
30419087,CSF,with,risk of MCI
30419087,Ng Aβ42 T-tau,with,risk of MCI
30419087,P-tau,with,risk of MCI
30419087,Neither CSF T-tau P-tau,was associated with,risk of MCI
30419087,Ng,was associated with,risk of MCI
30419087,CSF Aβ42,for,risk of MCI
30419087,CSF NfL,for,risk of MCI
36216455,neuromyelitis optica spectrum disorder (NMOSD),to relapsing-remitting multiple sclerosis,(RRMS)
36216455,NMOSD (5.4±8.2 years),with,RRMS
36216455,RRMS,mean duration,NMOSD=5.8±1.9 (1.9-9.9) years
26590657,Neuromyelitis optica spectrum disorder (NMOSD),differs from,multiple sclerosis (MS)
26590657,NMOSD,from,MS
26590657,NMOSD,with relapsing-remitting MS,(RRMS)
26590657,NMOSD,from,RRMS patients
32740781,Multiple sclerosis (MS),in,MS
32740781,Multiple sclerosis (MS),in,NMOSD patients
32740781,Neuromyelitis optica spectrum disorder (NMOSD),in,NMOSD patients
32740781,CNS,in,NMOSD patients
32740781,MS,in,NMOSD patients
32740781,Anti-Müllerian hormone (AMH),in,MS
32740781,Anti-Müllerian hormone (AMH),in,NMOSD patients
32740781,NMOSD predominance,in,MS
32740781,NMOSD predominance,in,NMOSD patients
32740781,mean AMH serum levels,in,NMOSD group (r = - 0.402 p = 0.03 and r = - 0.457 p = 0.014 respectively)
32740781,AMH levels,in,MS
32740781,AMH levels,in,NMOSD patients
32740781,MS (RRMS),patients,23 seronegative NMOSD patients
32740781,AMH levels,were measured with,AMH Gen II Enzyme-Linked Immunosorbent Assay Beckman Coulter kit
32740781,AMH,in,RRMS group
32740781,The mean AMH levels,in,NMOSD group
32740781,mean serum AMH levels,between,RRMS
32740781,mean serum AMH levels,between,NMOSD patients
29984162,posterior thalamic radiation ROIs,from,(JHU-TBSS) 2
29984162,posterior thalamic radiation ROIs,from,(JUEL-TBSS)
29984162,(JHU-TBSS) 2,using,ConTrack (CON-PROB)
29984162,(JUEL-TBSS),using,ConTrack (CON-PROB)
29984162,a) NMOSD,with,prior ON (NMOSD-ON) b) CIS
29984162,a) NMOSD,with,early RRMS patients
29984162,prior ON (NMOSD-ON) b) CIS,with,ON (CIS/RRMS-ON)
29984162,prior ON (NMOSD-ON) b) CIS,with,c) CIS
29984162,prior ON (NMOSD-ON) b) CIS,with,early RRMS patients
29984162,early RRMS patients,with,ON (CIS/RRMS-ON)
29984162,early RRMS patients,with,c) CIS
29984162,ON (CIS/RRMS-ON),without,prior ON (CIS/RRMS-NON)
29984162,c) CIS,without,prior ON (CIS/RRMS-NON)
29984162,early RRMS patients,without,prior ON (CIS/RRMS-NON)
29984162,prior ON (CIS/RRMS-NON),against,healthy controls (HCs)
29984162,Twenty-three NMOSD,underwent,CIS/RRMS-ON 21 CIS/RRMS-NON
29984162,NMOSD,differed throughout,methodologies (p-values ranging from p < 0.0001 to 0.0043)
29984162,HC,differed throughout,methodologies (p-values ranging from p < 0.0001 to 0.0043)
29984162,JHU-TBSS (AUC = 0.756; R = 0.262),compared to,CON-PROB (AUC = 0.742; R = 0.179)
29984162,JHU-TBSS (AUC = 0.756; R = 0.262),compared to,JUEL-TBSS (AUC = 0.719; R = 0.161)
26521232,NMOSD,from,CIS/RRMS
36192175,MS discriminate RRMS,from,AQP4-NMOSD
36192175,MS discriminate RRMS,from,MOGAD
36192175,RRMS,from,AQP4-NMOSD
36192175,RRMS,over,MOGAD
36192175,RRMS,from,APQ4-NMOSD
36192175,RRMS,from,MOGAD
33227631,NMOSD-ON,in,NMOSD and RRMS eyes
33227631,NMOSD,in,NMOSD and RRMS eyes
33227631,RRMS,in,NMOSD and RRMS eyes
33227631,NMOSD groups,in,NMOSD and RRMS eyes
33227631,HCs no difference,in,NMOSD and RRMS eyes
33227631,HCs,in,NMOSD and RRMS eyes
33227631,MS,without,history of ON
33227631,NMOSD-ON,compared to,NMOSD
33227631,NMOSD,without,history of ON
33227631,RRMS,to,HCs
33227631,NMOSD groups,to,HCs
33227631,HCs no difference,was observed between,NMOSD
33227631,NMOSD,without,HCs
33227631,history of ON,compared to,non ON-eyes
33227631,NMOSD,compared to,MS patients
33227631,macular and retinal damage,occurred in,both NMOSD and RRMS patients
33227631,NMOSD,unlike,MS patients
28550707,CONCLUSIONS Certain miRNAs,in,miR-126-5p
28550707,CONCLUSIONS Certain miRNAs,in,contrast both miR-101-5p
28550707,neuromyelitis optica spectrum disorders (NMOSD),from relapsing-remitting multiple sclerosis,(RRMS)
28550707,NMOSD,in,contrast both miR-101-5p
28550707,NMOSD,in,miR-126-5p
28550707,NMOSD patients,with,intracranial lesions (NMOSD-IC)
28550707,CONCLUSIONS Certain miRNAs,are associated with,RRMS
28550707,CONCLUSIONS Certain miRNAs,are associated with,NMOSD
35316545,RRMS,with,anti-aquaporin-4 antibody-positive NMOSD (2 males and 16 females; mean age 52.67 ± 16.07 years)
35316545,anti-aquaporin-4 antibody-positive NMOSD (2 males and 16 females; mean age 52.67 ± 16.07 years),using,GM-based spatial statistical analysis
35316545,RRMS,showed reduced NDI,MVF
35316545,GM pathologies,in,RRMS
33905981,patients (13 MOGAD 24 RRMS and 14 AQP4-Ab NMOSD),demonstrated that,RRMS
33905981,MOGAD,were,large abnormalities (both predictive for MOGAD)
33905981,AQP4-Ab NMOSD,were,large abnormalities (both predictive for MOGAD)
33905981,large abnormalities (both predictive for MOGAD),to,lateral ventricle and cerebellum involvement (all predictive for MOGAD)
33905981,T1 hypointensity (all predictive for RRMS),as,large lesions (for MOGAD)
33905981,RRMS,versus,MOGAD
33905981,MOGAD,versus,AQP4-Ab NMOSD models
33905981,RRMS,versus,AQP4-Ab NMOSD models
33905981,distinction of MOGAD,from,RRMS
33905981,distinction of MOGAD,from,AQP4-Ab NMOSD
36215904,both rTMS,in,MCI
36215904,scientific literature NIBS,in,AD
36215904,scientific literature NIBS,in,MCI
36215904,efficacy of repetitive Transcranial Magnetic Stimulation (rTMS),applied in,AD
36215904,efficacy of repetitive Transcranial Magnetic Stimulation (rTMS),applied in,MCI
36215904,both rTMS,in,AD
36215904,AD clinical recommendation,can be made for,NEURO-AD system
36215904,NEURO-AD system,for,high-frequency rTMS
36215904,AD,in,MCI
34700007,efficacy of NIBS specifically repetitive transcranial magnetic stimulation (rTMS),on,NPS
34700007,different NIBS techniques disease populations,used to assess,NPS
35841242,immediate and long-term effect of non-invasive brain stimulation (NIBS),in,Alzheimer's disease (AD)
35841242,immediate and long-term effect of non-invasive brain stimulation (NIBS),in,AD
35841242,therapy effect of repetitive transcranial magnetic stimulation (rTMS),in,Alzheimer's disease (AD)
35841242,therapy effect of repetitive transcranial magnetic stimulation (rTMS),in,AD
35841242,rTMS,in,AD
35841242,therapy effect of rTMS tDCS,in,Alzheimer's disease (AD)
35841242,therapy effect of rTMS tDCS,in,AD
35841242,16 articles (including 372 AD patients treated with rTMS and 310 treated with sham rTMS),in,AD
35841242,11 articles (including 152 AD patients treated with tDCS and 134 treated with sham tDCS),in,AD
35841242,RTMS,in,AD
35841242,effect of NIBS,in,AD
35841242,16 articles (including 372 AD patients treated with rTMS and 310 treated with sham rTMS),for,rTMS
35841242,16 articles (including 372 AD patients treated with rTMS and 310 treated with sham rTMS),for,11 articles (including 152 AD patients treated with tDCS and 134 treated with sham tDCS)
35841242,AD,given,rTMS
33115936,Alzheimer's disease (AD),during,rTMS
33115936,mild cognitive impairment (MCI),during,rTMS
33115936,HFrTMS (1.08 9 0.35-1.80),had,short-term positive effects
33115936,rTMS,than,MCI
34432674,NIBS,in,both mild cognitive impairment and Alzheimer disease patients
34432674,optimal stimulation protocol of noninvasive brain stimulation (NIBS),including,repetitive transcranial magnetic stimulation (rTMS)
34432674,Low-frequency rTMS,over,(DLPFC) high-frequency rTMS (HF-rTMS)
26402010,recent rTMS studies,conducted in,AD patients
26402010,studies of rTMS treatment,on,AD patients
26402010,AD patients,with,cognitive impairment
26402010,total of 94 mild to moderate AD patients,were included in,This meta-analysis aimed to evaluate recent rTMS
26402010,more well-controlled rTMS studies,should be evaluated in,AD patients
34568342,rTMS stimulation,in,patients of MCI
34568342,rTMS stimulation,in,early AD
34568342,variety of rTMS parameters,including,distinctive stages of AD
34568342,cognitive enhancement of rTMS treatment,on,patients of MCI
34568342,cognitive enhancement of rTMS treatment,on,early AD
34764859,high-frequency rTMS stimulation of multiple sites,as,(2) more than 10 rTMS stimulation sessions
31842821,few rTMS trials,in,MCI
31842821,MCI we,in,MCI
31842821,MCI,to,AD dementia
31842821,effects of repetitive transcranial magnetic stimulation (rTMS),in,AD
31842821,few rTMS trials,have been conducted in,MCI we
31842821,MCI we,designed,short-term efficacy of rTMS
31842821,short-term efficacy of rTMS,in,MCI
31842821,20 bilateral rTMS treatment sessions participants,will be followed for,short-term efficacy
31842821,effects of rTMS,on,other cognitive measures symptoms of depression
31842821,rTMS,for,treatment of MCI
33546266,safety of NIBS,for,cognitive impairment
33546266,cognitive impairment,after,stroke
33546266,cognitive symptoms post-stroke,with,NIBS
36215848,Alzheimer's Disease Neuroimaging Initiative database,in,classifying AD
26572145,prognosis of Alzheimer's disease (AD),as,i.e. mild cognitive impairment (MCI)
26572145,Alzheimer's Disease Neuroimaging Initiative,using,baseline MRI and FDG-PET imaging data
26572145,(ADNI) database,using,baseline MRI and FDG-PET imaging data
29572601,(CNNs),for,AD classification
29572601,93 AD patients,from,Alzheimer's Disease Neuroimaging Initiative (ADNI) database
29572601,204 mild cognitive impairment (MCI 76 pMCI +128 sMCI),from,Alzheimer's Disease Neuroimaging Initiative (ADNI) database
31841947,AD,on,ADNI datasets
31841947,normal controls (NC) MCI,on,ADNI datasets
31841947,NC and MCI converters (MCI-C),on,ADNI datasets
31841947,AD,versus,normal controls (NC) MCI
31841947,normal controls (NC) MCI,versus,NC and MCI converters (MCI-C)
31841947,NC and MCI converters (MCI-C),versus,MCI non-converters (MCI-NC)
31841947,MCI non-converters (MCI-NC),on,ADNI datasets
36215796,ARHL,in,ARHL show promising results
36215796,loss,including,age-related hearing loss (ARHL)
36215796,loss,including,one of top neurodegenerative diseases
34685743,neurodegenerative conditions,as,II diabetes cardiovascular disease
34685743,IL-6 and white blood cells,are associated with,ARHL
27147466,enzymes driving protein phosphorylation acetylation methylation,may contribute to hearing,impairment
29017893,potential role of inflammation,in,age-related hearing loss (ARHL)
29017893,loss,as,C-reactive protein IL-6 and TNF
29017893,role of chronic inflammation,in hearing,loss
33775891,Post-translational modifications (PTMs),in,pathogenesis of NDDs
33775891,PI3K/Akt/GSK3β MAPK,in,pathogenesis of NDDs
33775891,AMPK pathway,in,pathogenesis of NDDs
33775891,Wnt,in,pathogenesis of NDDs
33775891,post-translational mechanism,for,instance molecular chaperone ubiquitin-proteasome system autophagy-lysosomal degradation pathway
33775891,PI3K/Akt/GSK3β MAPK,cascade,AMPK pathway
33775891,PI3K/Akt/GSK3β MAPK,cascade,Wnt
34539328,Both age-related hearing loss (ARHL),in,vestibular function (ARVL)
34539328,age-related loss,in,vestibular function (ARVL)
27667674,Age-related hearing loss (ARHL),is,most prevalent neurodegenerative disease
27667674,serum aldosterone levels,treated,middle age mice
27667674,severity of ARHL we,treated,middle age mice
27667674,middle age mice,with,aldosterone
27667674,post-translational protein modifications,were blocked by,aldosterone therapy
28474569,Alzheimer's disease (AD),is,neurodegenerative disorder
28474569,neurodegenerative disorder,recognized as,most common cause of chronic dementia
28474569,progressive loss of neurons,composed of,amyloid-β pelaques
28474569,progressive loss of neurons,composed of,neurofibrillary tangles (NFTs)
28474569,AD-related proteins,like,APP Aβ tau BACE1
28474569,APP Aβ tau BACE1,undergo,post-translational modifications
28474569,functionality of AD-related proteins,contributing to,development of AD pathology
33450070,response properties of postsynaptic bushy neurons,in,CBA/CaJ mice of either sex
33450070,CBA/CaJ mice of either sex,under,normal hearing
33450070,CBA/CaJ mice of either sex,under,age-related hearing loss (ARHL)
36215788,The databases PubMed EMBASE Web of Science CNKI,in,TCM
36215788,The databases PubMed EMBASE Web of Science CNKI,in,field of TCM
36215788,devising of TCM,presented,potential perspective of computer-aided TCM development
36215788,COVID-19,diabetes,(AD)
36116517,computer algorithms of TCM between 2000 and 2021,in,PubMed Web of Science China National Knowledge Infrastructure (CNKI) Elsevier
21253603,TCM Database@Taiwan (,is,world's largest non-commercial TCM database
34247564,specific TCM syndromes,will be issued with,development of AI-assisted TCM therapies
35841663,TCM,against,COVID-19
36215698,Exogenous erythropoietin normalizes,in,AD-model mice
36215698,Exogenous erythropoietin normalizes,in,systemic Aβ clearance and alleviates disease progression
36215698,brain Aβ levels,preventing,Alzheimer's disease pathogenesis
36215698,Erythropoietin,increases,phagocytic activity levels of Aβ-degrading enzymes
36215698,Erythropoietin,increases,Aβ
36215698,Alzheimer's-associated brain pathologies,in,AD-model mice
36215698,Exogenous erythropoietin normalizes,impaired,EPO signaling and dysregulated functions of peripheral macrophages
36215698,EPO signaling and dysregulated functions of peripheral macrophages,in,AD-model mice
36215698,EPO signaling and dysregulated functions of peripheral macrophages,in,systemic Aβ clearance and alleviates disease progression
33737172,Impaired amyloid-β (Aβ) clearance,in,Aβ clearance
33737172,Alzheimer's disease (AD),in,Aβ clearance
33737172,Smad3,signaling,regulated macrophage phagocytosis of Aβ
33737172,blocking Smad3 signaling,increased,Aβ clearance
33737172,APP/PS1 transgenic AD model mice,attenuated,Aβ deposition
33737172,APP/PS1 transgenic AD model mice,attenuated,neuroinflammation
33737172,Smad3,attenuated,Aβ deposition
33737172,Smad3,attenuated,neuroinflammation
33737172,Smad3 inhibition,attenuated,AD-related pathology
26363791,Amyloid-beta (Aβ),in,pathogenesis of Alzheimer's disease (AD)
26363791,brain-derived Aβ,in,Aβ clearance
26363791,AD,in,Aβ clearance
26363791,blood Aβ levels,on,AD pathogenesis
26363791,Aβ,in,expression of amyloid precursor protein Aβ
26363791,Aβ deposition,in,expression of amyloid precursor protein Aβ
26363791,brain Aβ burden,in,expression of amyloid precursor protein Aβ
26363791,peripheral Aβ clearance,in,Aβ clearance
26363791,brain-derived Aβ,for,AD
26363791,mice,used,effect of peripheral Aβ catabolism
26363791,effect of peripheral Aβ catabolism,on,AD pathogenesis
26363791,blood Aβ levels,in,inferior/posterior vena cava
26363791,expression of amyloid precursor protein Aβ,generating,degrading enzymes Aβ transport receptors
26363791,expression of amyloid precursor protein Aβ,generating,AD-type pathologies
26363791,loss,in,brains of parabiotic AD mice
26363791,brain Aβ,preventing,AD pathogenesis
23813967,EPO (125 µg/kg),in,AD
23813967,Neuro-EPO,in,AD
23813967,EPO (250 µg/kg),in,Bax level TNFα
23813967,EPO (250 µg/kg),in,Akt activation
23813967,Aβ₂₅₋₃₅-induced increase,in,Akt activation
23813967,EPO (125 µg/kg),in,Bax level TNFα
23813967,EPO (125 µg/kg),in,Akt activation
23813967,Bax level TNFα,in,Akt activation
23813967,two EPO formulations,in,rodent model of Alzheimer's disease (AD)
23813967,two EPO formulations,in,rHu-EPO
23813967,two EPO formulations,in,low sialic form Neuro-EPO
23813967,EPO (125 µg/kg),was tested at,Neuro-EPO
23813967,mouse hippocampus,were examined,cell loss
23813967,EPO (125 µg/kg),led to,significant prevention of Aβ₂₅₋₃₅-induced learning deficits
23813967,Neuro-EPO,led to,significant prevention of Aβ₂₅₋₃₅-induced learning deficits
23813967,EPO (250 µg/kg),prevented,Aβ₂₅₋₃₅-induced increase
23813967,EPO (125 µg/kg),prevented,Aβ₂₅₋₃₅-induced increase
23813967,Aβ₂₅₋₃₅-induced increase,in,Bax level TNFα
33828237,β (Aβ) accumulation,in,pathogenesis of Alzheimer's disease (AD)
33828237,β (Aβ) accumulation,in,sporadic AD
33828237,pathogenesis of Alzheimer's disease (AD),in,sporadic AD
33828237,approximately half of Aβ,in,pathogenesis of Alzheimer's disease (AD)
33828237,approximately half of Aβ,in,sporadic AD
33828237,Aβ,on,AD pathologies
33828237,Aβ,in,APP/PS1 mice
33828237,Furthermore therapeutic effects of diuretic furosemide,on,AD pathologies
33828237,Furthermore therapeutic effects of diuretic furosemide,in,APP/PS1 mice
33828237,Aβ clearance,on,AD pathologies
33828237,Aβ clearance,in,APP/PS1 mice
33828237,brain Aβ deposition,in,APP/PS1 mice
33828237,Tau hyperphosphorylation glial activation neuroinflammation,in,APP/PS1 mice
33828237,blood and brain Aβ levels,in,APP/PS1 mice
33828237,Furthermore therapeutic effects of diuretic furosemide,on,Aβ clearance
33828237,brain Aβ deposition,aggravated,AD pathologies
33828237,AD pathologies,including,Tau hyperphosphorylation glial activation neuroinflammation
33828237,AD pathologies,including,neuronal loss
33828237,addition chronic furosemide treatment,reduced,blood and brain Aβ levels
33828237,blood and brain Aβ levels,attenuated,AD pathologies
33828237,AD pathologies,in,APP/PS1 mice
32381118,Amyloid-beta (Aβ),in,pathogenesis of AD
32381118,Amyloid-beta (Aβ),in,clearance of Aβ
32381118,peripheral Aβ clearance,for,treatment of AD
25553822,Male Sprague-Dawley rats (200-250 g),in,effects of Epo
25553822,Male Sprague-Dawley rats (200-250 g),on,Aβ-induced impairments
25553822,injection of Aβ they,in,Aβ+Epo group
25553822,injection of Aβ they,in,Aβ+V group
25553822,Epo,in,Aβ+V group
25553822,Bilateral injection of Aβ,in,Aβ+Epo group
25553822,step-through latency (STL),in,Aβ+Epo group
25553822,effects of Epo,on,Aβ-induced impairments
25553822,Epo,in,Aβ+Epo group
25553822,Aβ+Epo group,in,Aβ+V group
25553822,Bilateral injection of Aβ,decreased,step-through latency (STL)
25553822,step-through latency (STL),whereas,12 day administration of Epo significantly improved memory performance
25553822,12 day administration of Epo significantly improved memory performance,in,Aβ+Epo group
25553822,Epo,improved,Aβ-induced deficits
33185814,miR-146a,in,TLR tolerance
33185814,expression of AD risk genes,in,non-AD littermates
33185814,Aβ,may cause,Aβ/LPS tolerance
33185814,TLR4 ligand,may cause,Aβ/LPS tolerance
33185814,Aβ/LPS tolerance,leading to decreased,Aβ clearance
33185814,Aβ deposit-bearing 12-month-old model mice of Alzheimer's disease (AD),compared with,non-AD mice
33185814,Aβ deposit-bearing 12-month-old model mice of Alzheimer's disease (AD),compared with,Aβ deposit-free 2-month-old AD mice
33185814,potential roles of miR-146a,in inducing,TLR tolerance
33185814,expression of AD risk genes,in,12-month-old AD mice
33185814,12-month-old AD mice,in,non-AD littermates
33185814,microglial Aβ/LPS tolerance,leading to,reduced Aβ clearance
30252487,Erythropoietin,in,rodent models of Alzheimer's disease (AD)
30252487,(EPO) glycoprotein cytokine,in,rodent models of Alzheimer's disease (AD)
30252487,BBB-penetrable analog of EPO,in,double transgenic mouse model of AD
30252487,APP/PS1 mice,in,APP/PS1 mouse model of AD
30252487,BBB-penetrable cTfRMAb-EPO fusion protein,in,APP/PS1 mouse model of AD
30252487,multiple targets of AD pathogenesis,in,APP/PS1 mouse model of AD
30252487,progression (Aβ load synaptic loss microglial activation),in,APP/PS1 mouse model of AD
30252487,transferrin receptor (cTfRMAb),acts as,Erythropoietin (EPO)
30252487,BBB-penetrable analog of EPO,on,AD pathology
30252487,AD pathology,in,double transgenic mouse model of AD
30252487,APP/PS1 mice,treated with,BBB-penetrable cTfRMAb-EPO fusion protein
30252487,BBB-penetrable cTfRMAb-EPO fusion protein,had,significantly lower cortical and hippocampal Aβ peptide number ( p < 0.05)
30252487,significantly lower cortical and hippocampal Aβ peptide number ( p < 0.05),in,hippocampal synaptic loss ( p < 0.05)
32973044,sEH,in,brains of both male and female familial Alzheimer's disease (5×FAD) model mice
32973044,The inhibition of sEH,in,brains of 6-month-old male 5×FAD mice
32973044,TPPU,in,brains of 6-month-old male 5×FAD mice
32973044,1415-EET,in,pathophysiology of AD
32973044,Notably higher concentration of 1415-EET (200 ng/ml) infusion,in,brains of 6-month-old male 5×FAD mice
32973044,EET,in,pathophysiology of AD
32973044,EET,in,pathophysiology of AD and therapeutic strategies
32973044,sEH inhibition,in,familial Alzheimer's disease (5×FAD) mice
32973044,β (Aβ),contributes to,pathophysiology of AD
32973044,soluble epoxide hydrolase,for,epoxyeicosatrienoic acid (EET)
32973044,(sEH)-a key enzyme,for,epoxyeicosatrienoic acid (EET)
32973044,sEH,with,1-trifluoromethoxyphenyl- 3-(1-propionylpiperidin-4-yl) urea (TPPU)
32973044,sEH,with,genetic deletion of reduces Aβ deposition
32973044,1-trifluoromethoxyphenyl- 3-(1-propionylpiperidin-4-yl) urea (TPPU),in,brains of both male and female familial Alzheimer's disease (5×FAD) model mice
32973044,genetic deletion of reduces Aβ deposition,in,brains of both male and female familial Alzheimer's disease (5×FAD) model mice
32973044,The inhibition of sEH,with,TPPU
32973044,1415-EET levels,in,brains of mice
32973044,TPPU,astrocyte,Aβ clearance
32973044,1415-EET,astrocyte,Aβ clearance
32973044,1415-EET,into,hippocampus of 5×FAD mice
32973044,hippocampus of 5×FAD mice,prevented,aggregation of Aβ
32973044,Aβ deposition,in,brains of 6-month-old male 5×FAD mice
32973044,EET,signaling,1415-EET
32973044,late-onset AD,to,pathophysiology of AD
32973044,sEH,increasing,1415-epoxyeicosatrienoic acid (EET)
32973044,1415-epoxyeicosatrienoic acid (EET),enhanced,amyloid-β (Aβ) clearance
32973044,aggregation of Aβ,reversed,deposition of Aβ
32973044,1415-EET,in,pathophysiology of AD and therapeutic strategies
36215429,Alzheimer's disease (AD) progression-associated genes,from,amnestic mild cognitive impairment (aMCI)
36215390,group of LYsosome-Enhancing Compounds (LYECs),in,dopamine transporters (DAT)
36215390,member of LYECs,in,dopamine transporters (DAT)
36215390,cognitive function of APP-PSEN1 mice,in,dopamine transporters (DAT)
36215390,group of LYsosome-Enhancing Compounds (LYECs),promote,activation of TFEB (transcription factor EB)
36215390,activation of TFEB (transcription factor EB),via inhibiting,dopamine transporters (DAT)
36215390,DAT inhibition,can alleviate,pathogenesis of Alzheimer's disease
36130073,9 (CDK9),in,TFEB
36130073,novel regulator of DAT-mediated lysosome biogenesis,in,TFEB
36130073,Transcription factor EB (TFEB)-mediated lysosome biogenesis,alleviates,neurodegenerative diseases
36130073,neurodegenerative diseases,underlying,TFEB
36130073,group of lysosome-enhancing compounds (LYECs),promote,TFEB activation
36130073,One of compounds LH2-051,inhibited,function of dopamine transporter (DAT)
36130073,9 (CDK9),as,novel regulator of DAT-mediated lysosome biogenesis
36130073,LH2-051,enhanced,degradation of amyloid beta plaques
36130073,degradation of amyloid beta plaques,improved,memory of amyloid precursor protein
36130073,degradation of amyloid beta plaques,improved,APP)/Presenilin 1 (PS1) mice
25031402,sporadic Alzheimer's disease,in,AD
25031402,elevated extracellular Aβ levels,in,AD
25031402,(AD) impaired Aβ removal,in,AD
25031402,Aβ localizes,in,AD
25031402,Aβ42,in,hippocampus of APP/PS1 transgenic mice
25031402,TFEB,in,hippocampus of APP/PS1 transgenic mice
25031402,activation of TFEB,in,AD
25031402,sporadic Alzheimer's disease,to,elevated extracellular Aβ levels
25031402,(AD) impaired Aβ removal,to,elevated extracellular Aβ levels
25031402,elevated extracellular Aβ levels,drive,amyloid plaque pathogenesis
25031402,transcription factor EB,would promote,Aβ
25031402,(TFEB) master regulator of lysosome biogenesis,would promote,Aβ
25031402,hippocampus of APP/PS1 transgenic mice,compared with,control virus-injected mice
25031402,adequate Aβ removal,in,AD
25031402,amyloid plaque pathogenesis,in,AD
27209302,clearance of Aβ,in,Alzheimer's disease (AD)
27209302,transcription factor EB,in,brain slices of APP/PS1 transgenic mice
27209302,transcription factor EB,in,AD
27209302,(TFEB) essential regulator,in,brain slices of APP/PS1 transgenic mice
27209302,(TFEB) essential regulator,in,AD
27209302,Aβ clearance,in,brain slices of APP/PS1 transgenic mice
27209302,Aβ clearance,in,AD
27209302,microglial expression of TFEB,in,TFEB
27209302,Aβ (fAβ) degradation,in,TFEB
27209302,SIRT1 overexpression,in,TFEB
27209302,lysosomal function and fAβ degradation,in,TFEB
27209302,overexpression of deacetylated TFEB,in,brain slices of APP/PS1 transgenic mice
27209302,overexpression of deacetylated TFEB,in,AD
27209302,K116R mutant,in,brain slices of APP/PS1 transgenic mice
27209302,K116R mutant,in,AD
27209302,intracellular fAβ degradation,in,brain slices of APP/PS1 transgenic mice
27209302,intracellular fAβ degradation,in,AD
27209302,deacetylation of TFEB,in,brain slices of APP/PS1 transgenic mice
27209302,deacetylation of TFEB,in,AD
27209302,fAβ degradation,in,AD
27209302,clearance of Aβ,by degrading,degrading them in lysosomes countering amyloid plaque
27209302,amyloid plaque pathogenesis,in,Alzheimer's disease (AD)
27209302,transcription factor EB,would promote,Aβ clearance
27209302,(TFEB) essential regulator,would promote,Aβ clearance
27209302,microglial expression of TFEB,facilitates,Aβ (fAβ) degradation
27209302,Aβ (fAβ) degradation,deposited,amyloid plaques
27209302,TFEB,at,lysine residue 116
27209302,SIRT1 overexpression,enhanced,lysosomal function and fAβ degradation
27209302,lysosomal function and fAβ degradation,by upregulating,transcriptional levels of TFEB downstream targets
27209302,transcriptional levels of TFEB downstream targets,could be inhibited,TFEB
27209302,overexpression of deacetylated TFEB,at,K116R mutant
27209302,deposited amyloid plaques,in,brain slices of APP/PS1 transgenic mice
27209302,deacetylation of TFEB,could regulate,fAβ degradation
27209302,fAβ degradation,making,microglial activation of TFEB possible strategy
27209302,microglial activation of TFEB possible strategy,for attenuating amyloid plaque deposition in,AD
35253615,novel TFEB activator,in,brain of P301S MAPT/tau
35253615,novel TFEB activator,in,3XTg mice two commonly used AD animal models
35253615,degradation of phosphorylated MAPT/tau aggregates,in,brain of P301S MAPT/tau
35253615,degradation of phosphorylated MAPT/tau aggregates,in,3XTg mice two commonly used AD animal models
35253615,TFEB-mediated autophagy,in,brain of P301S MAPT/tau
35253615,TFEB-mediated autophagy,in,3XTg mice two commonly used AD animal models
35253615,MAPT/tau pathology,in,brain of P301S MAPT/tau
35253615,MAPT/tau pathology,in,3XTg mice two commonly used AD animal models
35253615,Alzheimer disease (AD),is,most common neurodegenerative disease
35253615,AD,are,thus discovery of novel anti-AD agents
35253615,TFEB,regulates,(transcription factor EB) master regulator of autophagy
35253615,A compromised autophagy-lysosomal pathway (ALP),has been implicated in,AD progression
35253615,A compromised autophagy-lysosomal pathway (ALP),has been implicated in,TFEB-mediated ALP
35253615,A compromised autophagy-lysosomal pathway (ALP),has been implicated in,MAPT/tau aggregates
35253615,AD progression,is,promising anti-AD strategy
35253615,TFEB-mediated ALP,is,promising anti-AD strategy
35253615,MAPT/tau aggregates,is,promising anti-AD strategy
35253615,celastrol natural small molecule,with,anti-obesity effect
35253615,anti-obesity effect,is,novel TFEB activator
35253615,celastrol,promotes,degradation of phosphorylated MAPT/tau aggregates
35253615,celastrol,enhances,TFEB-mediated autophagy
35253615,celastrol,enhances,MAPT/tau pathology
35253615,TFEB-mediated autophagy,suggesting that,celastrol
35253615,MAPT/tau pathology,suggesting that,celastrol
35253615,celastrol,represents,novel anti-AD and other tauopathies drug candidate
34272505,AD treatment,in,AD patients
34272505,Aβ accumulation,in,APP/PSEN1 transgenic mice
34272505,cognitive dysfunction of AD,in,APP/PSEN1 transgenic mice
34272505,clearance of Aβ,in,aggregation of Aβ
34272505,AD mice,accompanied by,clearance of Aβ
34272505,nuclear TFEB,with,AMPK-mediated acetyl-CoA synthetase 2
34272505,AMPK-mediated acetyl-CoA synthetase 2,enhancing,transcription of genes
29967008,Transcription factor EB (TFEB),in,mouse model of Alzheimer's disease
29967008,TFEB,in,mouse model of Alzheimer's disease
29967008,PPARα,in,mouse model of Alzheimer's disease
29967008,peroxisome proliferator-activated receptor alpha (PPARα),in,mouse model of Alzheimer's disease
29967008,transcription factor EB,in,mouse model of Alzheimer's disease
29967008,aspirin,induced,activation of peroxisome proliferator-activated receptor alpha (PPARα)
29967008,activation of peroxisome proliferator-activated receptor alpha (PPARα),stimulated,transcription
29967008,oral administration of low-dose aspirin,decreased,amyloid plaque pathology
29967008,amyloid plaque pathology,in,both male and female 5X familial Alzheimer's disease (5XFAD) mice
29967008,both male and female 5X familial Alzheimer's disease (5XFAD) mice,in,PPARα-dependent fashion
29967008,PPARα,suggests that,low-dose aspirin
29967008,mouse model of Alzheimer's disease,via,PPARα
36215153,Regional brain iron accumulation,is observed in,many neurodegenerative diseases
36215153,many neurodegenerative diseases,including,Alzheimer's disease
33035667,iron,has been demonstrated in,amyloid plaques
36060596,AD and HC groups,in,AD
36060596,AD and HC groups,in,AD group (r=-0.510 P=0.005)
36060596,Widespread cortical iron,in,AD
36060596,Alzheimer's disease (AD) cerebral iron accumulation colocalizes,with,pathological proteins amyloid-β (Aβ)
36060596,significant atrophy magnetic susceptibility,was compared between,AD and HC groups
36060596,AD group,showed that increased susceptibility covaried with,lower MMSE
36060596,Increased iron content was,associated with,brain atrophy
33231528,mild cognitive impairment (MCI),with,β-amyloid
33231528,iron,with,β-amyloid
33231528,brain iron content,correlated with,β-amyloid
33062715,The insulin-resistant state,causes,iron overload
33062715,T2DM patients,exhibited,(26.78 ± 2.35; HCs 28.42 ± 0.64; normal standard ≥26)
33062715,(26.78 ± 2.35; HCs 28.42 ± 0.64; normal standard ≥26),than,HCs
28424610,pattern of iron accumulation,in,subcortical vascular mild cognitive impairment (svMCI)
28424610,brain iron deposition,in,svMCI subjects
28424610,19 SIVD patients,without,cognitive impairment
28424610,importance of iron deposition,in understanding,svMCI-associated cognitive deficits
34476177,motor functions (precentral and postcentral areas premotor cortex),in,visual processing (occipital gyri cuneus posterior cingulum fusiform calcarine and lingual gyrus)
30128274,Putative iron content,in,PD pathogenesis
30128274,Post-hoc test,in,PDD patients
30128274,PD patients,in,PDD patients
30128274,limbic structures of PDD and PD patients,in,PD pathogenesis
30128274,L-Dopa equivalent dosage,for,two PD groups (p = 0.125)
30128274,iron accumulation,in,limbic structures of PDD and PD patients
PubMed,36216518,is related to,35777803
PubMed,36216518,is related to,24634832
PubMed,36216518,is related to,33436035
PubMed,36216518,is related to,35061102
PubMed,36216518,is related to,31834392
PubMed,36216518,is related to,24132375
PubMed,36216518,is related to,30611311
PubMed,36216518,is related to,35925685
PubMed,36216518,is related to,30419087
PubMed,36216455,is related to,26590657
PubMed,36216455,is related to,32740781
PubMed,36216455,is related to,29984162
PubMed,36216455,is related to,26521232
PubMed,36216455,is related to,36192175
PubMed,36216455,is related to,33227631
PubMed,36216455,is related to,28550707
PubMed,36216455,is related to,35316545
PubMed,36216455,is related to,33905981
PubMed,36215904,is related to,34700007
PubMed,36215904,is related to,35841242
PubMed,36215904,is related to,33115936
PubMed,36215904,is related to,34432674
PubMed,36215904,is related to,26402010
PubMed,36215904,is related to,34568342
PubMed,36215904,is related to,34764859
PubMed,36215904,is related to,31842821
PubMed,36215904,is related to,33546266
PubMed,36215848,is related to,31021792
PubMed,36215848,is related to,31927474
PubMed,36215848,is related to,30788463
PubMed,36215848,is related to,26572145
PubMed,36215848,is related to,34713109
PubMed,36215848,is related to,35777803
PubMed,36215848,is related to,29572601
PubMed,36215848,is related to,31923610
PubMed,36215848,is related to,31841947
PubMed,36215796,is related to,35777803
PubMed,36215796,is related to,34685743
PubMed,36215796,is related to,27147466
PubMed,36215796,is related to,29017893
PubMed,36215796,is related to,33775891
PubMed,36215796,is related to,34539328
PubMed,36215796,is related to,27667674
PubMed,36215796,is related to,28474569
PubMed,36215796,is related to,33450070
PubMed,36215788,is related to,35777803
PubMed,36215788,is related to,36116517
PubMed,36215788,is related to,35076690
PubMed,36215788,is related to,21253603
PubMed,36215788,is related to,34875986
PubMed,36215788,is related to,34247564
PubMed,36215788,is related to,25666163
PubMed,36215788,is related to,33844136
PubMed,36215788,is related to,35841663
PubMed,36215698,is related to,33737172
PubMed,36215698,is related to,26363791
PubMed,36215698,is related to,23813967
PubMed,36215698,is related to,33828237
PubMed,36215698,is related to,32381118
PubMed,36215698,is related to,25553822
PubMed,36215698,is related to,33185814
PubMed,36215698,is related to,30252487
PubMed,36215698,is related to,32973044
PubMed,36215429,is related to,35777803
PubMed,36215429,is related to,34905304
PubMed,36215429,is related to,21386892
PubMed,36215429,is related to,16632515
PubMed,36215429,is related to,31035919
PubMed,36215429,is related to,32605541
PubMed,36215429,is related to,32271844
PubMed,36215429,is related to,31438848
PubMed,36215429,is related to,27272489
PubMed,36215390,is related to,36130073
PubMed,36215390,is related to,26338325
PubMed,36215390,is related to,25031402
PubMed,36215390,is related to,35777803
PubMed,36215390,is related to,35847498
PubMed,36215390,is related to,27209302
PubMed,36215390,is related to,35253615
PubMed,36215390,is related to,34272505
PubMed,36215390,is related to,29967008
PubMed,36215153,is related to,35777803
PubMed,36215153,is related to,33035667
PubMed,36215153,is related to,36060596
PubMed,36215153,is related to,33231528
PubMed,36215153,is related to,33062715
PubMed,36215153,is related to,28424610
PubMed,36215153,is related to,34476177
PubMed,36215153,is related to,30128274
PubMed,36215153,is related to,29722955
